A Comparative Study of Approved Drugs for SARS-CoV-2 by Molecular Docking
Open Access
- 30 June 2021
- journal article
- Published by Universitas Muhammadiyah Palangkaraya in Journal of Molecular Docking
- Vol. 1 (1), 25-31
- https://doi.org/10.33084/jmd.v1i1.2148
Abstract
SARS-CoV-2, a new type of Coronavirus, has affected more millions of people worldwide. From the spread of this infection, many studies related to this virus and drug designing for the treatment have been started. Most of the studies target the SARS-CoV-2 main protease, spike protein of SASR-CoV-2, and some are targeting the human furin protease. In the current work, we chose the clinically used drug molecules remdesivir, favipiravir, lopinavir, hydroxychloroquine, and chloroquine onto the target protein SARS-CoV-2 main protease. Docking studies were performed using Arguslab, while Discovery Studio collected 2D and 3D pose views with the crystal structure of COVID-19 main protease in complex with an inhibitor N3 with PDB ID 6LU7. Computational studies reveal that all ligands provided good binding affinities towards the target protein. Among all the chosen drugs, lopinavir showed the highest docking score of -11.75 kcal/mol. The results from this molecular docking study encourage the use of lopinavir as the first-line treatment drug due to its highest binding affinity.Keywords
This publication has 26 references indexed in Scilit:
- Full-Length Computational Model of the SARS-CoV-2 Spike Protein and Its Implications for a Viral Membrane Fusion MechanismViruses, 2021
- Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany—An Ethical AnalysisInternational Journal of Environmental Research and Public Health, 2021
- Furin: A Potential Therapeutic Target for COVID-19iScience, 2020
- Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targetingEuropean Journal of Pharmacology, 2020
- Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19Cellular Signalling, 2020
- Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategiesInternational Journal of Antimicrobial Agents, 2020
- Corrigendum to “World Health Organization declares Global Emergency: A review of the 2019 Novel Coronavirus (COVID-19)” [Int. J. Surg. 76 (2020) 71–76]International Journal of Surgery, 2020
- Coronavirus disease 2019 (COVID-19): current status and future perspectivesInternational Journal of Antimicrobial Agents, 2020
- COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeuticsHuman Vaccines & Immunotherapeutics, 2020
- Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus DiseasesACS Central Science, 2020